News &amp; Updates

Treatment delays do not necessarily contribute to cancer-specific survival (CSS) or locoregional recurrence (LRR) in patients with oropharynx carcinoma, reveals a study. However, time on treatment (TOT) of 1 to 3 days is associated with lower CSS.

Transgender people less likely to undergo cancer screening

Despite being at increased risk for breast and cervical cancer, transgender people experience inequalities in the uptake of routine cancer screening, a study has found.

15 Mar 2022

Lenvatinib + pembrolizumab improves PFS in East Asian patients with advanced RCC

15 Mar 2022 by

Lenvatinib + pembrolizumab combination regimen improves progression-free survival (PFS) compared with sunitinib in a subset of East Asian patients with advanced renal cell carcinoma (aRCC), a finding that was similar to that of the global population of the CLEAR* trial, according to a subanalysis presented at ASCO GU 2022.

Female, non-White oncologists get lower satisfaction scores from patients

Asian and Hispanic oncologists, as well as female oncologists treating genitourinary malignancies, receive lower patient satisfaction scores (PSS), according to a study.

Salvage chemotherapy better than surgery in patients with elevated tumour markers

Salvage chemotherapy is preferable over surgery in patients with alpha-fetoprotein (AFP) >30 µg/l and human chorionic gonadotropin (HCG) ≥20 mIU/ml after first-line chemotherapy, suggests a study.

Metabolic syndrome tied to risk of 11 cancers

Eleven different malignancies seem to be correlate with metabolic syndrome (MS), as well as with the presence of MS components, reports a recent study.

PPIs contribute to small increase in pancreatic cancer risk

Individuals exposed to high cumulative doses of proton pump inhibitors (PPIs) have a slightly elevated risk of pancreatic cancer, a study reports.

13 Mar 2022

Neoadjuvant chemotherapy worsens survival after breast reconstruction

Neoadjuvant chemotherapy may lead to worse overall survival in women who had undergone mastectomy and immediate breast reconstruction, a recent study has found.

Retzius-sparing robot-assisted radical prostatectomy deliver satisfactory positive surgical margin rate

The rates of positive surgical margin (PSM) with Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) are acceptable and higher in pT3 disease than in pT2, according to a study.